Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $71M (up 46.9% year over year) with net income of −$49M.
Q2 2026 key financials · XBRL
- Revenue
- $71M
- +46.9% YoY · +18.5% QoQ
- Net income
- −$49M
- −5.7% YoY · +11.4% QoQ
- Operating margin
- -68.1%
- EPS (diluted)
- −$0.74
- +1.3% YoY · +10.8% QoQ
Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) Q2 2026 10-Q on SEC EDGAR. USD.
RHYTHM PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $71.3M in Q2 2026, up 19% sequentially; no year-ago quarterly revenue disclosed
- U.S. revenue $51.0M, up $14.1M or 38% sequentially; ex-U.S. revenue $20.3M, down $2.9M or 13%
- Net loss $49.3M vs $46.6M YoY; operating-margin percentages not disclosed
- Cash, cash equivalents and short-term investments $330.9M at June 30, 2026; expected funding for at least 24 months
- Near-term milestones: Japan launch by year-end 2026, bivamelagon Phase 3 initiation by year-end 2026, Europe launches beginning 2027
Risk Factors
- Newly triggered CHI-program risk: February 2023 Xinvento acquisition remains discovery-stage, with no expected revenue for many years
- Most material financial update: continued losses, including $49.3 million quarterly net loss and $1,456.8 million accumulated deficit
- Regulatory risk: later-stage setmelanotide trials may fail to replicate earlier results, jeopardizing additional indications and approvals
- Near-term commercial risk: IMCIVREE commercialization remains early-stage across the United States, Canada, EU, and United Kingdom
- Liquidity risk: $330.9 million cash and investments may require supplementation as development and commercialization expenses increase
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RHYTHM PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.